CDIA
IMMU

Capital Directions Investment Advisors’s Immunomedics Inc IMMU Stock Holding History

Capital Directions Investment Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4
Closed – – 121
2018
Q3 		$0 Buy
+4
New +$95 ﹤0.01% 243

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Capital Directions Investment Advisors's IMMU Position: Q4 2018 in Review

Capital Directions Investment Advisors sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 4 shares.

Capital Directions Investment Advisors first reported a position in IMMU in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • Capital Directions Investment Advisors reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • Capital Directions Investment Advisors sold 4 Immunomedics Inc shares in Q4 2018.
  • Capital Directions Investment Advisors first reported a position in Immunomedics Inc in Q3 2018 and held it in 1 quarter.
  • Capital Directions Investment Advisors's Immunomedics Inc position peaked at $0 in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Capital Directions Investment Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.